The purpose of this expert review is to discuss the impact of nanotechnology in the treatment
of the major health threats including cancer, infections, metabolic diseases, autoimmune …

Respiratory syncytial virus (RSV) infection is now recognised as a significant problem in
elderly adults. Epidemiological evidence indicates the impact of RSV in older adults may be …

Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory
pathogens of paramount medical significance that exert high mortality. At present, there is no …

The two nonstructural (NS) proteins NS1 and NS2 of respiratory syncytial virus (RSV) are
abundantly expressed in the infected cell but are not packaged in mature progeny virions …

Schefflera heptaphylla is a popular medicinal plant in southern China. Three caffeoylquinic
acid derivatives, namely 3, 4-di-O-caffeoylquinic acid, 3, 5-di-O-caffeoylquinic acid, and 3-O …

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract
infections worldwide, yet no effective vaccine or antiviral treatment is available. Here we …

Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Gene silencing by siRNA (short interfering RNA) is a still developing field in biology and has
evolved as a novel post-transcriptional gene silencing strategy with therapeutic potential …

Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality worldwide,
causing severe respiratory illness in infants and immune compromised patients. The ciliated …

Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) cause a similar
spectrum of respiratory infections in humans. Classified within the Paramyxoviridae family …